About Megakaryon
About Megakaryon
Company name
Megakaryon Corporation
Founded
September 9th, 2011
Locations
Kyoto office/Kyoto Lab
Kyoto Research Park
134 Minamimachi, Chudoji,
Shimogyo-ku, Kyoto,
600-8813,
JAPAN
Capitalization
¥3,602,873,611
Officers
  • Kenichi Akamatsu Kenichi Akamatsu, PH.D.
    CEO&COO, President
  • Koichi Samizo Koichi Samizo, MBA, Ph.D.
    Director, Chief Strategy Officer
  • Tsuyoshi Ayabe Tsuyoshi Ayabe, MBA
    Director, Chief Financial Officer
  • Yoshihiro Kumagae Yoshihiro Kumagae, Ph.D.
    Chief Technology Officer
  • Takehiko Sawabe,MBAExternal Director (INCJ, Ltd.)
  • Hidetsugu MishibaAudit and supervisory committee member
  • Genjiro Miwa, MBAAudit and supervisory committee member, and Founder
  • Takeshi KawanoAudit and supervisory committee member
  • Keisuke NakanoAudit and supervisory committee member
Company Objectives
By utilizing the regenerative potential of induced pluripotent stem (iPS) cells, we aim to produce high-quality platelets and other blood products that are safe, with reliable supply on demand and are affordable while independent of blood donations.
Shareholders
Genjiro Miwa; Koji Eto; Hiromitsu Nakauchi; Motoo Watanabe; Kenichi Akamatsu; INCJ, Ltd.; SBI INVESTMENT CO., LTD.; Otsuka Pharmaceutical Factory, Inc.; Otsuka Pharmaceutical Co., Ltd., Shinsei Corporate Investment Ltd.; Mizuho Capital Co., Ltd; SMBC Venture Capital Co., Ltd.; Miyako Capital.; Ltd.; Mitsubishi UFJ Capital Co., Ltd.; Satake Chemical Equipment Mfg Ltd.; SEKISUI CHEMICAL CO., LTD.; iPS Academia Japan, Inc.; iCELL Inc.; Japan Asia Investment Co., Ltd.; KSP, Inc.; Nissay Capital Co., Ltd.; DBJ Capital Co., Ltd.; The Shiga Bank Ltd.; Kyoto Seisakusho Co., Ltd.; CMIC Holdings Co., Ltd.; Sysmex Corporation;
ScientificAdvisors/Collaborators
Hiromitsu Nakauchi

Hiromitsu Nakauchi, MD, Ph.D.

Director, Center for Stem Cell Biology and Project Professor, Division of Stem Cell Therapy
Professor of Genetics Institute for Stem Cell Biology and Regenerative Medicine, Stanford University

Koji Eto

Koji Eto, MD, Ph.D.

Professor of Center for iPS Cell Research and Application, Kyoto University
Professor of Innovative Regenerative Medicine, Graduate School of Medicine, Chiba University

George Q. Daley MD,Ph.D.

George Q. Daley MD,Ph.D.

Dean of Harvard Medical School,
Professor of Biological Chemistry and Molecular Pharmacology, Harvard Medical School; Director, Stem Cell Transplantation Program, Boston Children’s Hospital

Mahendra S. Rao MD,Ph.D.

Mahendra S. Rao MD,Ph.D.

Vice President for Regenerative Medicine, New York Stem Cell Foundation Research Institute
former Director of the NIH Center for Regenerative Medicine

Sherrill J. Slichter MD,Ph.D.

Sherrill J. Slichter MD,Ph.D.

Professor of Medicine, Division of Hematology, University of Washington School of Medicine

George J. Murphy MD,Ph.D.

George J. Murphy MD,Ph.D.

Asst. Professor of Medicine, Hematology and Oncology Section, Boston University School of Medicine

Alan D. Michelson、MD

Alan D. Michelson,MD

Professor of Medicine and Pediatrics, Harvard　Medical School
Director, Center for Platelet Research Studies, Children's Hospital Boston
Joint appointment, Brigham and Women's Hospital

A.L. Larry Frelinger III, Ph.D

A.L. Larry Frelinger III, Ph.D

Assistant Professor of Pediatrics, Harvard　Medical School
Associate Director, Center for Platelet Research Studies, Children's Hospital Boston
Joint Appointment, Dana Farber Cancer Institute

History

2011

  • September Megakaryon was founded to commercialize the research results of Prof. Nakauchi's and Prof. Eto's research teams that were recognized as an Adaptable and Seamless Technology Transfer Program through Target-driven Research and Development (A-STEP*) project under Japan Science and Technology (JST) Agency.Capital: 10 million.

2013

  • August Additional funding of ￥1,160 million raised through private shares managed by Innovation Network Corporation of Japan, SMBC Venture Capital Co., Ltd., Mizuho Capital Co., Ltd., and Mitsubishi UFJ Capital Co., Ltd.
  • September Kyoto Lab opened at the Kyoto University Hospital Campus.

2014

  • April Cell Processing Center (CPC) completed at the Kyoto Lab.
  • NovemberKyoto office/Kyoto Lab opened in Kyoto.

2015

  • MarchCompany officially recognized as a Designated Core Business within the Kansai National Strategic Special Zone.
  • March Additional ¥2,540 million raised through private shares managed by Innovation Network Corporation of Japan; SMBC Venture Capital Co., Ltd.; Mitsubishi UFJ Capital Co., Ltd.; Mizuho Capital Co., Ltd.; Japan Asia Investment Co., Ltd.; DBJ Capital Co., Ltd.; Nissay Capital Co., Ltd.; KSP, Inc.; and Miyako Capital.
  • November Commenced collaborative research with Harvard University (Boston Children's Hospital)

2016

  • April The Japan Agency for Medical Research and Development (AMED) has recognized our project for "Focused on Developing Key Evaluation Technology: Evaluation for Industrialization in the Field of Regenerative Medicine."
  • May Kyoto Office and Kyoto Lab expansion.

2017

  • June Featured at the Japan-US Innovation Awards Symposium, 2017 held at Stanford　University.
  • December ¥3, 700 million raised through private shares managed by Innovation Network Corporation of Japan; Otsuka Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Factory, Inc. Sysmex Corporation, CIMIC Holdings Co., Ltd., Kyoto Seisakusho Co., Ltd, Satake Chemical Equipment Mfg Ltd., Shinsei Corporate Investment Ltd., Miyako Capital Co., Mizuho Capital Co., The Shiga Bank Ltd., REVIC Capital Co., Ltd., SMBC Venture Capital Co., Ltd.; Mitsubishi UFJ Capital Co., Ltd.

2018

  • JuneMegakaryon selected for the J-Startup Program.

2020

  • FebruaryMegakaryon Corporation along with the partner companies won the Minister of State for Science and Technology Policy Award at the 2nd Japan Open Innovation contest.
  • FebruaryAdditional ￥2,800 million raised through private shares.
pagetop